Roy, P. et al. 2026. Magnitude of Survival Benefit Associated With Tyrosine Kinase Inhibitors in Advanced Thyroid Carcinoma: A Systematic Review and Meta-Analysis Incorporating Updated Long-Term Evidence From SELECT (Lenvatinib) and COSMIC-311 (Cabozantinib) Trials. World Journal of Oncology. 17, 5 (Jan. 2026), 599–613. DOI:https://doi.org/10.14740/wjon2842.